Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...

On its way out the door, the Biden administration is proposing that Medicare and Medicaid cover Ozempic and other GLP-1 drugs ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

For a long time, dieting and exercise were the only realistic options for many people who wanted to lose weight, but recent ...

PGC-1α research offers new hope for weight loss by boosting metabolic efficiency and providing accessible management ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

The drug's development was funded by Novo Nordisk, the maker of popular semaglutide drugs like Ozempic and Wegovy. While these GLP-1 receptor agonists are effective in weight management, they often ...

Up to 30% of weight lost with GLP-1 drugs like Ozempic comes ... In cases of significant weight loss, the process of removing old bone and forming new bone might be slowed, potentially leading ...

How GLP-1 therapies could help build a healthier, more productive workforce—and what that would mean for how we live together ...